Barrett’s Oesophagus: What It Means After Long-Term Reflux

Barrett’s oesophagus is a change in the cells lining the lower part of the oesophagus—the tube that carries food from the mouth to the stomach. It is most often associated with years of gastro-oesophageal reflux, where stomach contents repeatedly travel upwards and irritate the oesophagus.

Being told that Barrett’s oesophagus is a “pre-cancerous condition” can sound alarming. It does increase the risk of one type of oesophageal cancer, but the individual risk remains low for most people. Most people diagnosed with Barrett’s oesophagus never develop cancer.

The purpose of follow-up is to identify the minority whose cells begin to develop more concerning changes, known as dysplasia. Regular acid-suppressing treatment and appropriate surveillance allow these changes to be found and treated at an early stage.

What is Barrett’s oesophagus?

The normal lining of the oesophagus is made from flat cells called squamous cells. These cells are designed to cope with food passing down the oesophagus, but they are not well suited to repeated exposure to stomach acid and digestive juices.

In Barrett’s oesophagus, some of the normal squamous lining near the stomach is replaced by taller, column-shaped cells that more closely resemble cells found in the stomach or intestine.

This change is called metaplasia. It is thought to be an adaptation to repeated injury from reflux.

Barrett’s oesophagus usually affects the lower part of the oesophagus, immediately above the point where it joins the stomach. The affected area may be:

• short segment, measuring less than 3 centimetres;
• long segment, measuring 3 centimetres or more.

The length matters because longer segments are generally associated with a greater likelihood of dysplasia and influence how often surveillance may be offered.

What is intestinal metaplasia?

When biopsies are examined under a microscope, the pathologist may look for specialised cells called goblet cells. Their presence is described as intestinal metaplasia.

In UK guidance, the diagnosis of Barrett’s oesophagus generally requires a clearly visible segment of abnormal lining measuring at least 1 centimetre above the junction with the stomach, confirmed through biopsies.

Very small or irregular areas around the junction are not always managed in the same way, particularly if intestinal metaplasia is absent.

Is Barrett’s oesophagus an ulcer?

No. Barrett’s oesophagus is a change in the type of cells lining the oesophagus.

An oesophageal ulcer is an open sore caused by inflammation or injury. A person can have reflux inflammation, an ulcer and Barrett’s changes at the same time, but they are separate findings.

Is it the same as oesophagitis?

No. Oesophagitis means active inflammation of the oesophageal lining. Barrett’s oesophagus describes a longer-term cellular change.

Someone may have Barrett’s oesophagus without visible inflammation during their gastroscopy, particularly when reflux is well controlled with medication.

How does long-term reflux lead to Barrett’s oesophagus?

Gastro-oesophageal reflux disease, usually shortened to GORD, develops when stomach contents repeatedly flow upwards into the oesophagus.

The stomach lining is designed to tolerate acid. The oesophageal lining is more vulnerable. Repeated exposure can cause inflammation, erosions and, in some people, a gradual change in the type of cells lining the lower oesophagus.

Reflux does not contain acid alone. It may also contain:

• digestive enzymes;
• bile from the upper small bowel;
• partially digested food;
• gas and stomach fluid.

Barrett’s oesophagus appears to be the body’s attempt to create a lining that is more resistant to this repeated chemical exposure. The new lining may tolerate reflux better, but it is also more likely than normal squamous lining to develop abnormal cellular changes over time.

Does everyone with reflux develop Barrett’s oesophagus?

No. Reflux is extremely common, while Barrett’s oesophagus develops in only a proportion of people with long-standing symptoms.

The likelihood appears to depend on a combination of:

• how long reflux has been present;
• how severe or frequent it is;
• genetic susceptibility;
• age;
• sex;
• body-fat distribution;
• smoking;
• other anatomical and biological factors.

Many people have reflux for years without developing Barrett’s oesophagus. Conversely, some people diagnosed with Barrett’s report little or no obvious heartburn.

Can silent reflux cause Barrett’s oesophagus?

Yes. A person can have significant reflux without recognising classic burning heartburn.

Possible less obvious symptoms include:

• a sour or bitter taste;
• frequent throat clearing;
• a chronic cough;
• hoarseness;
• night-time coughing;
• food or fluid coming back up;
• unexplained dental enamel erosion.

Some people have no noticeable symptoms and learn they have Barrett’s oesophagus during a gastroscopy performed for another reason.

Our guide to acid reflux and GORD explains the wider range of reflux symptoms and treatments.

Who is more likely to develop Barrett’s oesophagus?

Barrett’s oesophagus can affect anyone, but it is diagnosed more frequently in some groups.

Recognised risk factors include:

• long-standing or frequent acid reflux;
• being older, particularly over 50;
• being male;
• being overweight, especially carrying excess weight around the waist;
• smoking or a history of smoking;
• a hiatus hernia;
• a family history of Barrett’s oesophagus or oesophageal adenocarcinoma.

Abdominal weight and reflux

Excess weight around the abdomen increases pressure on the stomach and can encourage its contents to move upwards through the lower oesophageal sphincter.

Abdominal obesity may also influence inflammation and metabolic signalling independently of reflux.

Weight reduction can improve reflux symptoms in people who are overweight, although losing weight does not necessarily make established Barrett’s tissue disappear.

Hiatus hernia

A hiatus hernia develops when part of the stomach moves upwards through the opening in the diaphragm.

This can weaken the normal anti-reflux barrier and make stomach contents more likely to travel into the oesophagus.

Not everyone with a hiatus hernia develops reflux or Barrett’s oesophagus, and many small hernias cause no symptoms.

Smoking

Smoking can weaken the lower oesophageal sphincter, aggravate reflux and increase the risk of oesophageal cancer.

Stopping smoking is valuable even after Barrett’s oesophagus has been diagnosed because it reduces several wider cancer, heart and lung risks.

Does alcohol cause Barrett’s oesophagus?

Alcohol can worsen reflux in some people by relaxing the lower oesophageal sphincter and irritating the upper digestive tract.

However, the relationship between alcohol itself and Barrett’s oesophagus is less direct than the links with reflux, abdominal obesity and smoking.

A person does not need to avoid every alcoholic drink solely because Barrett’s has been diagnosed, but reducing or avoiding alcohol may be sensible when it triggers reflux or when advised for another health reason.

What symptoms does Barrett’s oesophagus cause?

Barrett’s oesophagus itself often causes no distinct symptoms. Most symptoms come from the reflux that contributed to the cellular changes.

Possible symptoms include:

• heartburn;
• a burning feeling behind the breastbone;
• acid or food coming back into the throat;
• a sour or bitter taste;
• indigestion;
• burping;
• nausea;
• upper abdominal discomfort;
• night-time cough;
• hoarseness;
• difficulty swallowing.

The severity of symptoms does not reliably show how much Barrett’s tissue is present or whether dysplasia has developed.

A person with severe heartburn may have no Barrett’s oesophagus, while someone with a long segment may have minimal symptoms because the changed cells are less sensitive to acid.

Why reflux can improve after Barrett’s develops

The column-shaped lining in Barrett’s oesophagus may be less sensitive than normal squamous cells. Some people therefore notice less burning despite continuing reflux.

This apparent improvement does not mean the reflux has resolved or the oesophagus no longer needs treatment and monitoring.

Symptoms that should not be ignored

New or progressive symptoms require assessment, even when a person is already in a Barrett’s surveillance programme.

Contact a GP promptly if you develop:

• difficulty swallowing;
• food repeatedly sticking in the throat or chest;
• pain when swallowing;
• persistent vomiting;
• unexplained weight loss;
• loss of appetite;
• vomiting blood;
• black, tar-like stools;
• new persistent chest or upper abdominal pain;
• iron-deficiency anaemia without a clear explanation.

Difficulty swallowing is sometimes caused by inflammation or a benign narrowing called a stricture, but it can also be a symptom of oesophageal cancer and should be investigated.

The NHS guide to oesophageal cancer symptoms explains the warning signs that need checking.

How is Barrett’s oesophagus diagnosed?

Barrett’s oesophagus is usually diagnosed through a gastroscopy, also called an upper gastrointestinal endoscopy.

During the procedure, a thin flexible camera is passed through the mouth and down the oesophagus. The endoscopist examines the lining and records:

• whether Barrett’s-type tissue is visible;
• where the affected area begins and ends;
• the length of the segment;
• whether there is active inflammation;
• whether there are ulcers, narrowing, nodules or other visible abnormalities;
• whether a hiatus hernia is present.

Biopsies

Tiny tissue samples are taken from the abnormal-looking area and sent to a laboratory.

The biopsies help determine:

• whether the tissue represents Barrett’s oesophagus;
• whether intestinal metaplasia is present;
• whether there is inflammation;
• whether dysplasia has developed;
• whether there is early cancer.

Taking biopsies is generally painless because the oesophageal lining does not sense the small samples in the same way skin would.

The Seattle biopsy protocol

During Barrett’s surveillance, NICE recommends high-resolution endoscopy with a systematic biopsy method known as the Seattle protocol.

This involves:

• targeted biopsies from any visible lesion;
• four-quadrant biopsies taken at regular intervals along the Barrett’s segment.

The approach is used because dysplasia may be present in a small area that does not look obviously abnormal.

What do C and M measurements mean?

An endoscopy report may use the Prague classification, with measurements labelled C and M.

• C describes the length of the continuous circular Barrett’s segment;
• M describes the maximum upward extent, including tongues of Barrett’s tissue.

For example, C2M4 means there are 2 centimetres of continuous Barrett’s lining, with the longest extension reaching 4 centimetres.

What if biopsies do not show intestinal metaplasia?

Sometimes the oesophagus looks like Barrett’s during endoscopy, but the biopsies do not confirm intestinal metaplasia.

This can occur because the affected cells were not captured in the small samples or because the visible change has another explanation.

A repeat gastroscopy may be recommended. NICE advises against routine surveillance for a short segment under 3 centimetres without intestinal metaplasia once the finding has been confirmed at two endoscopies.

Our guide to gastroscopy and what to expect explains preparation, sedation, biopsies and recovery.

What does dysplasia mean?

Dysplasia means the Barrett’s cells have developed additional abnormal changes that may precede cancer.

It does not mean that cancer is already present.

Biopsy results may be reported as:

• no dysplasia;
• indefinite for dysplasia;
• low-grade dysplasia;
• high-grade dysplasia;
• oesophageal adenocarcinoma.

No dysplasia

This means Barrett’s cells are present, but the pathologist has not identified pre-cancerous changes.

This is the result received by most people with Barrett’s oesophagus. Acid control and surveillance may be recommended according to segment length and individual risk.

Indefinite for dysplasia

Sometimes inflammation makes cells look abnormal, but the pathologist cannot confidently decide whether true dysplasia is present.

The result may be reported as indefinite for dysplasia. Treatment usually involves optimising acid suppression and repeating endoscopy and biopsies after inflammation has had time to settle.

NICE currently advises considering surveillance at six-month intervals with optimised acid-suppressing medication for people with indefinite dysplasia.

Low-grade dysplasia

Low-grade dysplasia means the cells have early pre-cancerous changes.

The diagnosis can be difficult because inflammation may mimic dysplasia. NICE recommends confirmation from two gastrointestinal pathologists and biopsies taken at two separate endoscopies before radiofrequency ablation is offered.

Confirmed low-grade dysplasia carries a higher risk of progression than Barrett’s oesophagus without dysplasia, but it can often be treated successfully through endoscopy.

High-grade dysplasia

High-grade dysplasia means the cells are severely abnormal and have a substantial likelihood of containing or progressing to early cancer.

It is not necessarily invasive cancer, but it requires prompt specialist treatment.

Visible abnormal areas are usually removed through endoscopic resection. Remaining Barrett’s tissue is then treated, often with radiofrequency ablation.

Why expert pathology review matters

Distinguishing inflammation, low-grade dysplasia and high-grade dysplasia can be difficult.

A diagnosis that could lead to endoscopic treatment or surgery is therefore usually reviewed by pathologists with specialist gastrointestinal experience.

How likely is Barrett’s oesophagus to become cancer?

Barrett’s oesophagus increases the risk of oesophageal adenocarcinoma, a cancer arising from gland-forming cells in the lower oesophagus.

However, the absolute risk for an individual with non-dysplastic Barrett’s remains low. Cancer Research UK states that fewer than 1 in 100 people with Barrett’s develop oesophageal adenocarcinoma in any one year, and most never develop it.

Risk is not the same for everyone. It is influenced by:

• whether dysplasia is present;
• the grade of dysplasia;
• the length of the Barrett’s segment;
• age;
• sex;
• smoking history;
• family history of oesophageal cancer;
• abdominal obesity;
• other individual factors.

Why Barrett’s is called pre-cancerous

The term means the changed cells have the potential to progress through stages that may eventually lead to cancer.

The usual proposed sequence is:

1. normal squamous lining;
2. Barrett’s metaplasia;
3. low-grade dysplasia;
4. high-grade dysplasia;
5. oesophageal adenocarcinoma.

Most people do not progress through this entire sequence. Some remain stable for decades, and some Barrett’s changes are discovered late in life without ever causing harm.

Can cancer develop between surveillance appointments?

Yes, although surveillance is designed to reduce this risk. No monitoring programme can prevent or detect every cancer.

New swallowing difficulty, unexplained weight loss, bleeding or persistent worsening symptoms should be reported rather than waiting for the next scheduled gastroscopy.

Does treating reflux remove the cancer risk?

Controlling reflux helps heal inflammation and manage symptoms, but it does not completely remove the cancer risk once Barrett’s tissue is established.

This is why some people still need surveillance even when proton pump inhibitor treatment has eliminated heartburn.

How often is Barrett’s oesophagus monitored?

Surveillance means having planned examinations to look for dysplasia or early cancer before symptoms develop.

The decision to offer surveillance should take account of:

• the length of the Barrett’s segment;
• whether intestinal metaplasia is confirmed;
• biopsy results;
• age and general health;
• family history;
• smoking history;
• whether the person would be suitable for treatment if an abnormality were found;
• the individual benefits and risks of repeated endoscopy.

Current NICE surveillance intervals

At present, NICE recommends offering high-resolution endoscopic surveillance with systematic biopsies:

• every 2 to 3 years for long-segment Barrett’s measuring 3 centimetres or more;
• every 3 to 5 years for short-segment Barrett’s under 3 centimetres when intestinal metaplasia is present.

The exact timing within those ranges should be tailored according to cancer risk factors such as age, sex, family history and smoking history.

These intervals apply to Barrett’s without confirmed dysplasia. Dysplasia requires a different and usually more intensive pathway.

Why might surveillance be stopped?

Continuing surveillance may not be beneficial when:

• serious health conditions make endoscopy risky;
• life expectancy is limited by another illness;
• the person would not be able or willing to undergo treatment if dysplasia were found;
• repeated endoscopies have not confirmed intestinal metaplasia in a very short segment;
• the burdens outweigh the likely benefit.

This should be an individual, shared decision rather than a rule based on age alone.

Capsule sponge tests

A capsule sponge test involves swallowing a small capsule attached to a thread. The capsule dissolves in the stomach and releases a compressed sponge, which is gently withdrawn and collects cells from the oesophagus.

Products include Cytosponge and EndoSign.

Capsule sponge testing is used in some Scottish services and is being evaluated or introduced through projects in other parts of the UK. It may help identify or monitor some people without immediately requiring gastroscopy.

It does not yet replace endoscopy in every situation, especially when dysplasia, a visible lesion or cancer is suspected.

How is Barrett’s oesophagus treated?

Treatment depends on whether dysplasia is present.

For Barrett’s without dysplasia, management usually focuses on:

• controlling reflux;
• healing inflammation;
• reducing exposure of the oesophagus to acid;
• surveillance where appropriate;
• reducing modifiable cancer risks such as smoking.

For confirmed dysplasia, treatment is usually aimed at removing visible abnormalities and destroying the remaining Barrett’s lining.

Proton pump inhibitors

Proton pump inhibitors, or PPIs, reduce the amount of acid produced by the stomach.

Common examples include:

• omeprazole;
• lansoprazole;
• esomeprazole;
• pantoprazole;
• rabeprazole.

They can:

• reduce heartburn and regurgitation;
• heal reflux oesophagitis;
• reduce ongoing acid exposure;
• make biopsy interpretation easier when inflammation is present.

A person with Barrett’s may be advised to continue a PPI even if symptoms are mild. The dose should be reviewed and adjusted according to symptom control, inflammation and specialist advice.

Do not stop long-term PPI treatment suddenly without discussing it with the prescribing clinician. Rebound acid production can cause a temporary but substantial return of symptoms.

H2-receptor antagonists and antacids

H2-receptor antagonists reduce acid, but generally less powerfully than PPIs. They may be used in selected circumstances or alongside other measures.

Antacids and alginates can provide short-term symptom relief. They do not treat dysplasia or replace surveillance.

Endoscopic mucosal resection

Endoscopic mucosal resection, often shortened to EMR, removes a visible abnormal area from the oesophageal lining.

The removed tissue can then be examined in detail to determine:

• whether dysplasia or cancer is present;
• how deeply abnormal cells extend;
• whether the area appears completely removed;
• whether surgery or further endoscopic treatment is needed.

NICE recommends endoscopic resection as first-line treatment for visible lesions associated with high-grade dysplasia and for many stage T1a early cancers.

Radiofrequency ablation

Radiofrequency ablation, or RFA, applies controlled heat energy to the surface lining of the oesophagus.

The treated Barrett’s tissue is destroyed, allowing a new lining to grow as the oesophagus heals.

RFA is commonly used:

• after visible lesions have been removed;
• for confirmed low-grade dysplasia;
• for high-grade dysplasia;
• to treat remaining Barrett’s tissue after early cancer has been removed endoscopically.

Several treatment sessions may be needed. Follow-up remains essential because Barrett’s tissue or dysplasia can recur.

Cryotherapy and other endoscopic treatments

Specialist centres may use cryotherapy, which destroys abnormal tissue through freezing, or other ablation techniques when radiofrequency treatment is unsuitable or incomplete.

Surgery

Removing part or most of the oesophagus is called an oesophagectomy.

Major surgery is now less commonly required for dysplasia or very early superficial cancer because many cases can be treated endoscopically.

It may still be recommended when cancer has grown more deeply, has high-risk features or cannot be removed completely through endoscopy.

Anti-reflux surgery

Procedures such as laparoscopic fundoplication strengthen the barrier between the stomach and oesophagus and may improve reflux in carefully selected patients.

NICE advises that anti-reflux surgery should not be offered specifically to prevent Barrett’s oesophagus progressing to dysplasia or cancer.

It may still be considered for ordinary GORD treatment when medication does not provide adequate symptom control or is unsuitable.

Should aspirin be taken to prevent cancer?

No one should start aspirin solely because they have Barrett’s oesophagus.

NICE advises against offering aspirin specifically to prevent progression to dysplasia or cancer. Aspirin can cause stomach irritation and gastrointestinal bleeding.

People already prescribed aspirin for heart or vascular disease should continue according to their clinician’s advice.

What can you do to control reflux and reduce risk?

Lifestyle measures cannot guarantee that Barrett’s oesophagus will regress or prevent cancer, but they can improve reflux and wider health.

Take prescribed acid suppression consistently

PPIs generally work best when taken regularly and at the correct time.

Many are most effective when taken before food, often before breakfast. People using a twice-daily regimen may be advised to take the second dose before the evening meal.

Follow the instructions for the particular medicine because timing and formulation can vary.

Identify personal triggers

Common reflux triggers may include:

• large meals;
• high-fat meals;
• alcohol;
• chocolate;
• peppermint;
• coffee;
• spicy food;
• tomatoes and acidic foods;
• fizzy drinks.

Not every trigger affects every person. Unnecessarily eliminating a long list of foods can make eating restrictive without improving symptoms.

A symptom diary may help identify genuine patterns.

Avoid lying down soon after eating

Try to leave approximately three hours between the final substantial meal and lying down for sleep.

Remaining upright allows gravity to help keep stomach contents below the oesophagus.

Raise the head of the bed

For night-time reflux, raising the head end of the bed by around 10 to 20 centimetres may help.

A wedge or blocks beneath the bed are generally more effective than adding ordinary pillows, which can bend the body at the waist and increase abdominal pressure.

Work towards a sustainable weight

Where excess abdominal weight is contributing to reflux, modest weight loss can improve symptoms and reduce pressure on the stomach.

Crash diets and rapid weight-loss methods are unnecessary. A gradual approach is more sustainable and reduces the chance of nutritional problems.

Stop smoking

Stopping smoking may improve reflux and reduces the risk of oesophageal cancer, heart disease, stroke and several other cancers.

Limit alcohol when it worsens symptoms

Alcohol can relax the lower oesophageal sphincter and worsen night-time reflux.

Reducing the amount, avoiding drinking near bedtime or stopping completely may help, depending on the person’s symptoms and overall health.

Keep surveillance appointments

Surveillance cannot help if appointments are repeatedly missed.

Contact the endoscopy service if you have not received expected follow-up, have moved address or are uncertain when the next check should occur.

Frequently asked questions about Barrett’s oesophagus

Is Barrett’s oesophagus cancer?

No. Barrett’s oesophagus is a change in the cells lining the lower oesophagus. Most people do not have dysplasia, and most never develop cancer.

Why is Barrett’s called pre-cancerous?

The altered cells have a greater potential than normal oesophageal cells to develop dysplasia and eventually adenocarcinoma. “Pre-cancerous” describes increased potential, not inevitable progression.

What percentage of people with Barrett’s develop cancer?

The annual risk is below 1% overall, and it is substantially lower for many people with non-dysplastic Barrett’s. Risk rises when low-grade or high-grade dysplasia is confirmed.

Can Barrett’s oesophagus go away?

The visible segment may occasionally become smaller, particularly with excellent reflux control, but complete and permanent disappearance is uncommon without ablation treatment.

Even when biopsies no longer detect intestinal metaplasia, previous findings may still influence follow-up because sampling can miss small areas.

Can a PPI reverse Barrett’s oesophagus?

PPIs control acid and heal inflammation but do not reliably remove established Barrett’s tissue. Their main role is reflux control rather than physically eliminating the altered cells.

Can Barrett’s be cured?

Endoscopic resection and ablation can remove or destroy Barrett’s tissue containing dysplasia. Long-term follow-up is still required because abnormal tissue may recur.

Does Barrett’s always cause heartburn?

No. Some people have little or no heartburn. Barrett’s may be discovered during a gastroscopy requested for anaemia, swallowing problems or another reason.

Can you have Barrett’s without reflux?

Yes. Some people do not recognise reflux symptoms, although silent or previous reflux may still have contributed.

Does the length of Barrett’s matter?

Yes. A longer segment is generally associated with greater progression risk and is currently monitored more frequently than a short segment.

What is a short-segment Barrett’s oesophagus?

It means the visible Barrett’s lining measures less than 3 centimetres. When intestinal metaplasia is present, current NICE guidance generally recommends surveillance every 3 to 5 years.

What is long-segment Barrett’s oesophagus?

It means the affected lining measures 3 centimetres or more. Current NICE guidance generally recommends surveillance every 2 to 3 years when there is no dysplasia.

What does “Barrett’s without dysplasia” mean?

It means the altered Barrett’s lining is present, but biopsies have not shown pre-cancerous cellular abnormalities.

What does “indefinite for dysplasia” mean?

It means the cells look abnormal, but inflammation or another factor prevents the pathologist from confidently deciding whether true dysplasia is present. Stronger acid suppression and repeat biopsies are often recommended.

Is low-grade dysplasia cancer?

No. It is an early pre-cancerous change. When confirmed by specialist pathology and repeat endoscopy, it is often treated with radiofrequency ablation.

Is high-grade dysplasia cancer?

Not necessarily, but it is very close to early cancer in the progression pathway and requires prompt specialist treatment.

Can Barrett’s cause difficulty swallowing?

Reflux inflammation or scarring may cause narrowing, but new swallowing difficulty must be investigated because it can also indicate dysplasia or cancer.

Should I worry if reflux symptoms suddenly improve?

Not automatically. Treatment may be working. However, Barrett’s tissue can sometimes be less sensitive to acid, so symptom improvement does not prove that the condition has disappeared.

Can I drink coffee with Barrett’s oesophagus?

Yes, unless coffee clearly worsens your reflux. There is no universal Barrett’s diet requiring everyone to avoid coffee.

Can I drink alcohol?

Moderate alcohol may be possible for some people, but it can worsen reflux. Reducing or avoiding it is sensible when it triggers symptoms or conflicts with other medical advice.

What foods should be avoided?

Avoid foods that repeatedly trigger your own reflux rather than following an unnecessarily restrictive universal list. Large, late and high-fat meals are common triggers.

Do I need to take omeprazole for life?

Many people with Barrett’s remain on long-term PPI treatment. The medicine, dose and duration should be reviewed individually rather than stopped without advice.

Are long-term PPIs dangerous?

PPIs can have side effects and may be associated with certain risks, but they are also highly effective medicines. For someone with Barrett’s, the benefits of controlling acid often outweigh the potential risks. Treatment should be reviewed periodically rather than stopped because of general online warnings.

Can reflux surgery prevent cancer?

Anti-reflux surgery may improve reflux symptoms but is not recommended specifically as a cancer-prevention treatment for Barrett’s oesophagus.

Do I need regular blood tests?

Barrett’s oesophagus itself is monitored mainly through endoscopy or other specialised oesophageal tests. Blood tests may be needed when there is anaemia, bleeding, nutritional concern or long-term treatment requiring review.

Can Barrett’s oesophagus run in families?

Family history appears to influence risk. Tell your specialist if a close relative has Barrett’s oesophagus or oesophageal adenocarcinoma, as this may affect the surveillance discussion.

What happens if I miss my surveillance gastroscopy?

Contact the endoscopy service or GP and ask for the appointment to be rearranged. Missing one appointment does not mean cancer has developed, but repeated delays reduce the value of surveillance.

Should symptoms be ignored between surveillance tests?

No. New swallowing difficulty, weight loss, persistent vomiting, bleeding or worsening symptoms should be reported promptly rather than waiting for the next scheduled appointment.